Clinical-stage biotech advancing ATH434 for Multiple System Atrophy (MSA). Positive Phase 2 results. FDA-aligned Phase 3 program. ASX: ATH, NASDAQ: ATHE
Joined April 2019
- Tweets459
- Following119
- Followers302
- Likes485
@AlterityT CEO David Stamler, will join a Fireside Chat at the Craig-Hallum Virtual Biotech Catalyst Conference on Thursday, 22 October at 2:30pm ET.
The archived webcast will be available afterward on the Alterity website. #ASX #ATH434 #biotech
📽️WEBINAR REPLAY | MST Financial
@AlterityT CEO David Stamler discusses ATH434 Phase 2 results, progress towards Phase 3 & the development pathway for Multiple System Atrophy (MSA).
$ATH starts at 33:52, with Q&A at 49:07.
#ATH #ATHE #ATH434
youtu.be/0Yg4BKmF0mI?si=b7uu…
@AlterityT will present at the Canaccord Genuity Drug & Device Conference on 12 October. Dr David Stamler will update investors on ATH434 Phase 2 results in MSA, progress toward Phase 3 & Alterity’s broader neurodegenerative disease program. 🕒 3:50pm AEST #ASX $ATH #Biotech #MSA
Alterity Therapeutics retweeted
Telix Launches FDA-Approved Pixclara in the U.S. as First Commercial Doses Delivered for Glioma Imaging - For More Information Visit tinyurl.com/8p49sxhy @TelixPharma #Glioma #Rare_Diseases #FDA #Brain_Cancer #Orphan_Drugs #Cancer_research #Cancer_imaging
Additional Phase 2 analyses presented at the MDS Congress in Seoul show ATH434 50mg BID slowed functional decline in #MSA after accounting for baseline disease severity. $ATH $ATHE Coverage via @StockheadAU stockhead.com.au/health/alte…
Alterity Therapeutics retweeted
Alterity Therapeutics CEO speaks with Proactive at the ASX SMIDcaps Conference @AlterityT proactiveinvestors.com/compa… #Pharmaceuticals #Biotechnology #David #Stamler #AlterityTherapeuticsLimited #NeurodegenerativeDisease #ASX
Alterity Therapeutics retweeted
52% functional decline slowing as @AlterityT ATH434 Phase 2 MSA data detailed at Seoul Congress $ATH
stockwirex.com/asx-stock-new…
New ATH434-201 Phase 2 analyses in Multiple System Atrophy presented at #MDSCongress 2026 in Seoul 💙hermes-cdn.investorhub.com/a… #MSA #Parkinsons
Today is World MSA Day. A day to raise awareness of Multiple System Atrophy and recognise its impact on people living with MSA, their carers, families and loved ones. Help us spread the word by sharing this post to raise awareness of MSA.
#MSA #raredisease #MSAawareness
MSA (Multiple System Atrophy) is our immediate focus, but the biology ATH434 targets is shared across other neurodegenerative diseases.
stockhead.com.au/health/the-…
#ASX #Biotech #Neurodegeneration #MSA
Alterity Therapeutics (ASX: ATH | NASDAQ: ATHE) will present at the ASX SMIDcaps Conference next Wednesday, 23 September, at 1:55pm AEST.
Alterity Therapeutics retweeted
USPTO patent protection strengthens @AlterityT’s ATH434 Parkinson’s investment case through 2045, supporting its long-term development and commercial potential.
vist.ly/5h5cz
#longevity #parkinsonsdisease #biotech #investment #patents
ALT Alterity Therapeutics logo with text about new Parkinson's patent.
Alterity Therapeutics retweeted
.@AlterityT will boost its funding position by at least $4.2 million through the exercise of options ahead of a pivotal trial for its lead drug candidate ATH434. buff.ly/ODPoHYB #ASX $ATH $ATHE
@AlterityT secures at least $4.2m from options ahead of key Phase III MSA trial.
Coverage via @StockheadAU
stockhead.com.au/health/alte…
#clinicaltrial #MSA #raredisease #ASX #biotech ethereum:0xbe0ed4138121ecfc5c0e56b40517da27e6c5226b
Catch the replay of @AlterityT presentation at the @CG_Driven Growth Conference (GC2026), where David Stamler shared an update on ATH434's progress toward Phase 3 in Multiple System Atrophy.
Watch the replay ⤵️alteritytx.com/events-and-pr…
Join our CEO Dr David Stamler live on 26 Aug for a webinar on ATH434 - MSA, the science, Phase 2 data, and the road to Phase 3. Presentation followed by live Q&A. Register ⏩zoom.us/webinar/register/311…
#ASX #ATH434
Alterity Therapeutics retweeted
Watch our webinar with @AlterityT, featuring Managing Director, CEO Dr David Stamler.
The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask David any questions about ATH that you may have.
Key Topics:
• What is MSA
• The Science and ATH434
• Phase 2 Clinical Trial Data
• The Road to Phase 3
• Catalysts and Outlook
Register now: hubs.la/Q04tvQ5n0
#ASX #Stocks #Shares
Alterity Therapeutics retweeted
Tylah Tully catches up with @AlterityT CEO David Stamler to discuss the company’s newly granted US #patent for ATH434, what it means for the drug’s long-term commercial potential, and the path towards a pivotal Phase 3 trial. buff.ly/2wCIG80 #ASX $ATH $ATHE
Host @tylahtully catches up with @AlterityT CEO David Stamler to discuss the company's newly granted US patent for ATH434, what it means for the drug's long-term commercial potential, and the path towards a pivotal Phase 3 trial. #ATH434 #MSA #Biotech
theaustralian.com.au/busines…
David Stamler, MD talks FDA alignment on ATH434's path to Phase 3, and what a successful trial could mean for the ~50,000 people living with MSA in the US.
neurologylive.com/view/ath43…
#MSA #ATH434 #RareDisease
